

## January 2019 APC Decisions

Medicine	Status	Indication	Other Information
<b>Semglee</b> (Insulin glargine biosimilar, Mylan)	<b>Amber 2</b>	<b>Diabetes</b>	<ul style="list-style-type: none"> <li>Available as a pre-filled pen or cartridge</li> <li>First line insulin glargine product for new patients</li> <li>Prescribe by brand</li> <li><a href="#">APC Biosimilar Briefing</a></li> </ul>
<b>Sodium chloride 7% &amp; Sodium chloride 3% solution for inhalation</b>	<b>Amber 2</b>	<b>Respiratory</b>	For assisted clearance of airway secretions in children and young people where this is complicated by high secretion viscosity
<b>Alkindi</b> (Hydrocortisone granules in capsules, Diurnal Ltd)	<b>Amber 2</b>	<b>Cortisol replacement</b>	<ul style="list-style-type: none"> <li>For cortisol replacement therapy for children (0-&lt;18 years) with adrenal insufficiency.</li> <li>0.5mg, 1mg and 2mg strengths available</li> </ul>
<b>DEKAs</b> (Multivitamins in CF, Alveolus Biomedical BV) <b>Paravit-CF</b> (Multivitamins, ParaPharm Development Limited)	<b>Amber 2</b>	<b>CF</b>	For Cystic fibrosis patients only The most cost effective preparation suitable for the patient should be chosen

## News from the APC

### Recently ratified documents:

- [Lithium prescribing information sheet \(Update\)](#)
- [Cows Milk allergy guidelines \(Update\)](#)
- [Managing Behaviour and Psychological Problems in Dementia \(Update\)](#)
- [Midodrine prescribing information sheet \(Update\)](#)
- [Growth Hormone Shared Care Protocol and Information sheet \(Update\)](#)
- [Vitamin D for Children Guideline \(Update\)](#)
- [Amiodarone prescribing information sheet \(Update\)](#)

## Amiodarone monitoring reminder

Ongoing monitoring in primary care:

Frequency	Required tests					Ophthalmological
	TFTs*	LFT	U&E	Chest X ray	ECG	
6 monthly	√	√	√			
12 monthly				√	√	√**

Also ask about breathlessness and non-productive cough, relating to possible pulmonary toxicity, at each review visit

\*TFTs should be measured for up to 12 months following discontinuation (**amiodarone has a half-life of 20 to 100 days**). Serum TSH should be measured when thyroid dysfunction is suspected.

\*\* And any time that new or worsening visual symptoms occur (a common side effect is a “blue halo” effect when looking into bright lights at nighttime). Encourage patient to attend optometrist annually.

**A written letter from the GP for the patient to take to the optometrist is required, to ensure annual monitoring by the optometrist is completed**

## Horizon Scanning, Formulary amendments and traffic light changes

Horizon scanning - Grey classification assigned until formal submission is requested

- Metformin for PCOS - Classified as **GREY**
- Spironolactone for hirsutism in PCOS - Classified as **GREY**
- Hyalofemme vaginal moisturiser - Classified as **GREY**
- Xonvea for nausea and vomiting in pregnancy - Classified as **GREY**
- Fusacomb Easyhaler - Classified as **GREY**
- Bupival (buprenorphine inj) - Classified as **GREY**
  
- ◇ Intravaginal Oestrogens - Clarified the traffic light status as **GREEN**
- ◇ Dapagliflozin - Clarity on use in renal impairment
- ◇ Fobumix Easyhaler - Added to the formulary as **GREEN**
- ◇ Duloxetine - Updated from **AMBER 2** to **GREEN** restricted to 3rd line
- ◇ Ubidecarenone - Clarified as **AMBER 2**.
- ◇ Fostair NEXThaler - Updated to include MART therapy

### Current work in development

- ⇒ HRT Formulary choice summary
- ⇒ Osteoporosis guideline and bisphosphonate prescribing information
- ⇒ Naltrexone prescribing information sheet
- ⇒ Chronic constipation pathway
- ⇒ Antimicrobial Guidelines (Update)
- ⇒ Anticoagulation in AF and DOAC information sheet (Update)

### Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Acute cough (including acute bronchitis)	Antimicrobial Guideline	February 2019
Depression in children and young people: identification and management	Guideline	April 2019
Prostate cancer: diagnosis and management	Guideline	April 2019
Urinary incontinence and pelvic organ prolapse in women : management	Guideline	April 2019
UrigoStart for treating leg ulcers and diabetic foot ulcers	Medical Technologies Guideline	January 2019

The work of the NAPC is supported and managed by the interface team below. They can be contacted via [MACCG.NottsAPC@nhs.net](mailto:MACCG.NottsAPC@nhs.net) if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Lynne Kennell, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust

Karen Robinson, APC and Formulary Support Technician, Nottinghamshire Health Community

Jill Theobald, Specialist Interface Efficiencies Pharmacist, Greater Nottingham CCP

Nick Sherwood, Specialist Mental Health Efficiencies Pharmacist, Notts Healthcare Trust